phrykt

Aktis Oncology, Inc. (AKTS): who owns it and who trades it

As of Nov 16, 2026, AKTS insiders reported 11 open-market sales worth $3.2M and 6 purchases worth $79.3M in the last 12 months, with 0% of the sale value made under pre-set 10b5-1 plans. The largest seller was Akos Czibere (Chief Medical Officer), with $1.6M. 5 of the 50 famous funds we follow held it at their last quarter end.

Latest filing Nov 16, 2026. From Form 4, 13F and Schedule 13D/G filings.

At a glance

Who is buying and selling Aktis Oncology

From the latest filings

Overall: more buying than selling. Insiders mostly sold. Funds and famous investors mostly bought.

Mostly sellingEvenMostly buying

Each group counts equally in the meter, by the number of buyers and sellers, not dollars. Insider sales under pre-set 10b5-1 plans are left out of it. From SEC, House and Senate filings; not advice.

Who owns AKTS

115 funds and institutions reported AKTS shares worth $1.1B at the end of Q2 2026. The largest holder is Mpm Bioimpact LLC with $156M.

10 largest owners, by value

Mpm Bioimpact LLC$156M
EcoR1 Capital, LLC$155M
Blue Owl Capital Holdings LP$99M
BlackRock, Inc.$73.4M
T. Rowe Price Investment Management, Inc.$66.1M
Wellington Management Group LLP$63.4M
Rtw Investments, LP$51.3M
Ra Capital Management, L.P.$42.4M
Jupiter Topco LLC$42.4M
Baker Bros. Advisors LP$32.1M

Top 20 owners

OwnerShares% of companyValueChange since Q1 2026
Mpm Bioimpact LLC4.84M–$156MNo change
EcoR1 Capital, LLC4.82M–$155MNo change
Blue Owl Capital Holdings LP3.07M–$99M-3%
BlackRock, Inc.2.28M–$73.4M+8%
T. Rowe Price Investment Management, Inc.2.05M–$66.1M-3%
Wellington Management Group LLP1.97M–$63.4M-15%
Rtw Investments, LP1.59M–$51.3MNo change
Ra Capital Management, L.P.1.31M–$42.4M-13%
Jupiter Topco LLC1.31M–$42.4MNew
Baker Bros. Advisors LP996,351–$32.1MNo change
Octagon Capital Advisors LP960,847–$31MNo change
Merck & Co., Inc.952,844–$30.7MNo change
Vanguard Capital Management LLC817,075–$26.3M-2%
T. Rowe Price Associates763,499–$24.6M-51%
TCG Crossover Management, LLC696,560–$22.5MNew
Geode Capital Management, LLC520,737–$16.8M+6%
Eventide Asset Management, LLC507,000–$16.3MNo change
Avidity Partners Management LP484,200–$15.6M-48%
State Street Corp484,010–$15.6M+13%
A16z Capital Management, L.L.C.415,000–$13.4MNo change

From the SEC 13F data sets: every fund manager with over $100M must report its US stock holdings every 3 months, up to 45 days after the quarter ends. Owners are shown as they file, so one group (for example Vanguard) can appear under several names. Individuals, most insiders and smaller funds do not file 13F reports.

Insider trades

In the last 12 months, AKTS insiders reported $79.3M of open-market purchases and $3.2M of sales. 0% of the sale value was under a 10b5-1 plan, a schedule set up in advance.

Purchases, 12 months
$79.3M
6 trades, 4 people
Sales, 12 months
$3.2M
11 trades, 3 people
Sales under a 10b5-1 plan
0%
Share of sale value
Latest trade
Sep 23, 2026
Filed Sep 24, 2026

Purchases and sales by month

$79.3M$79.3MDecFebAprJunAugOct
Purchases Sales Click a bar to show only that month below

Latest trades

DateInsiderRoleTypeSharesPriceValueFiling
Sep 23, 2026Akos CzibereChief Medical OfficerSale5,099$20.19$103KForm 4
Sep 23, 2026Akos CzibereChief Medical OfficerSale7,401$21.03$156KForm 4
Jul 20, 2026Ken HerrmannDirectorSale1,350$24.56$33.2KForm 4
Jul 20, 2026Ken HerrmannDirectorSale3,506$24.56$86.1KForm 4
Jul 17, 2026Ken HerrmannDirectorSale3,065$25.21$77.3KForm 4
Jul 8, 2026Shulamit Ron-BiggerChief Operating OfficerSale4,200$28.75$121KForm 4
Jul 8, 2026Shulamit Ron-BiggerChief Operating OfficerSale30,000$27.94$838KForm 4
Jul 8, 2026Shulamit Ron-BiggerChief Operating OfficerSale15,800$27.13$429KForm 4
Jul 8, 2026Akos CzibereChief Medical OfficerSale14,800$27.13$402KForm 4
Jul 8, 2026Akos CzibereChief Medical OfficerSale30,829$27.95$862KForm 4
Jul 8, 2026Akos CzibereChief Medical OfficerSale4,371$28.71$125KForm 4
Jan 12, 2026Todd FoleyDirectorPurchase232,870$18.00$4.2MForm 4
Jan 12, 2026Mpm Oncology Innovations Fund Lp +710% ownerPurchase1.11M$18.00$20MForm 4
Jan 12, 2026Oleg Nodelman +1DirectorPurchase2.08M$18.00$37.4MForm 4
Jan 12, 2026Oleg Nodelman +1DirectorPurchase144,443$18.00$2.6MForm 4
Jan 12, 2026Vida Ventures Ii-A, Llc +110% ownerPurchase22,545$18.00$406KForm 4
Jan 12, 2026Vida Ventures Ii-A, Llc +110% ownerPurchase812,455$18.00$14.6MForm 4

Insiders by value traded

InsiderRoleBoughtSoldLast trade
Oleg NodelmanDirector$40M–Jan 12, 2026
Mpm Oncology Innovations Fund Lp10% owner$20M–Jan 12, 2026
Vida Ventures Ii-A, Llc10% owner$15M–Jan 12, 2026
Todd FoleyDirector, 10% owner$4.2M–Jan 12, 2026
Akos CzibereChief Medical Officer–$1.6MSep 23, 2026
Shulamit Ron-BiggerChief Operating Officer–$1.4MJul 8, 2026
Ken HerrmannDirector–$197KJul 20, 2026
What this data shows, and what it doesn't
  • Shows: open-market purchases and sales by officers, directors and 10%+ owners, reported on Form 4 within two business days of the trade.
  • Leaves out: stock awards, option exercises, shares withheld for tax and gifts. These are not trades at a market price chosen by the insider.
  • "plan" marks a sale made under a Rule 10b5-1 plan, a schedule set up in advance.
  • Fund holders come from 13F reports, a snapshot at quarter end filed up to 45 days later.
  • Filings are self-reported and can be amended. Each trade links to its original filing. Methodology

AKTS short interest

4.43M AKTS shares are sold short. Over the last 12 reports the number of shares short went up 75%.

As of Oct 30, 2026, 4.43M AKTS shares were sold short, up 2.6% from the report before. At the average daily volume of 276,236 shares, buying them all back would take about 16.0 trading days (days to cover).

Shares short

4.43MMay 15Oct 305.04M

Days to cover

16.0May 15Oct 3020.4

Every report

Settlement dateShares short% of sharesChangeAvg daily volumeDays to cover
Oct 30, 20264.43M–+3%276,23616.0
Oct 15, 20264.31M–-9%382,80011.3
Sep 30, 20264.72M–+45%645,7217.3
Sep 15, 20263.25M–+2%281,99911.5
Aug 31, 20263.18M–-8%306,43210.4
Aug 14, 20263.45M–-1%229,68415.0
Jul 31, 20263.47M–-7%270,28912.8
Jul 15, 20263.74M–+13%597,2866.3
Jun 30, 20263.31M–+13%662,2265.0
Jun 15, 20262.91M–+9%251,95811.6
May 29, 20262.67M–+6%145,04218.4
May 15, 20262.53M–-2%151,23616.7

Short sellers borrow shares and sell them, hoping to buy them back for less. A high number means many such bets are open. It does not say where the price will go. Source: FINRA equity short interest, reported by brokers twice a month (positions on the 15th and the last business day) and published about 7 business days later. % of shares uses the share count on the company's latest SEC filing. What short interest means · Most shorted stocks

Aktis Oncology company events

Aktis Oncology filed 6 reports on Form 8-K in the last 12 months, 1 of them about an important change (leadership). The latest was on Nov 12, 2026.

  1. Nov 12, 2026ResultsReleased financial results. Filing
  2. Aug 13, 2026ResultsReleased financial results. Filing
  3. May 11, 2026ResultsReleased financial results. Filing
  4. Apr 16, 2026LeadershipDeparture of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangement of Certain Officers. Filing
  5. Mar 30, 2026ResultsReleased financial results. Filing
  6. Jan 12, 2026RulesChanged its bylaws or articles. Filing

From 8-K reports, which a company must file within 4 business days of an important event. Where a report is about a change such as a new CEO, the sentence is the first one from the report itself, shortened. Each row links to the original filing. Company events this week

Famous investors that hold AKTS

5 of the 50 well-known investors we track reported holding AKTS in their latest 13F filing. The largest position is Israel Englander's, worth $3.8M.

Position size

All holders

FundQuarterSharesValueOf portfolioChange
Israel Englander · Millennium ManagementQ3 2026192,728$3.8M0.0%New
Steve Cohen · Point72 Asset ManagementQ3 2026132,886$2.6M0.0%New
Ken Griffin · Citadel AdvisorsQ3 2026115,857$2.3M0.0%+354%
Jim Simons · Renaissance TechnologiesQ3 202630,539$595K0.0%-68%
Paul Tudor Jones · Tudor Investment CorpQ3 202624,980$486K0.0%+17%

From 13F reports: a snapshot at quarter end, filed up to 45 days later. Change compares with the quarter before.

5%+ stakes filed in the last 120 days

Anyone who owns more than 5% of a company must report it on Schedule 13D or 13G. 2 filings named AKTS in the last 120 days.

FiledHolderFormStake
Nov 16, 2026T. Rowe Price Investment Management, Inc.13G6.2%
Nov 16, 2026T. Rowe Price Investment Management, Inc.13G6.2%

Questions about Aktis Oncology, Inc. (AKTS) stock

Who owns the most AKTS stock?

The largest reported owner of Aktis Oncology, Inc. (AKTS) is Mpm Bioimpact LLC. In total, 115 funds and institutions reported holding AKTS at the end of Q2 2026. See the largest owners.

Are AKTS insiders buying or selling?

In the last 12 months, AKTS insiders reported 6 open-market purchases worth $79.3M and 11 sales worth $3.2M. The latest trade was on Sep 23, 2026. See every trade.

What is the short interest in AKTS?

As of Oct 30, 2026, 4.43M AKTS shares were sold short, up 2.6% from the report before. At the average daily volume of 276,236 shares, buying them all back would take about 16.0 trading days (days to cover). See the history.

Which famous investors hold AKTS?

5 of the 50 well-known investors we track reported AKTS in their latest 13F filing, including Israel Englander, Steve Cohen, Ken Griffin. The largest position is worth $3.8M. See all holders.

Source: SEC Form 4 (insiders, filed within 2 business days), 13F (funds, up to 45 days after quarter end) and Schedule 13D/13G filings. Only open-market purchases (code P) and sales (code S) are shown. Data only, not investment advice. How we collect it.